Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad137 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Abhishek N Prasad und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NIAID NIH HHS, Defense Threat Reduction Agency.
Abstract (Originalsprache)
Background
Highly pathogenic filoviruses such as Ebola virus (EBOV) hold capacity for delivery by artificial aerosols, and thus potential for intentional misuse. Previous studies have shown that high doses of EBOV delivered by small-particle aerosol cause uniform lethality in nonhuman primates (NHPs), whereas only a few small studies have assessed lower doses in NHPs.
Methods
To further characterize the pathogenesis of EBOV infection via small-particle aerosol, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona, which may help define risks associated with small particle aerosol exposures.
Results
Despite using challenge doses orders of magnitude lower than previous studies, infection via this route was uniformly lethal across all cohorts. Time to death was delayed in a dose-dependent manner between aerosol-challenged cohorts, as well as in comparison to animals challenged via the intramuscular route. Here, we describe the observed clinical and pathological details including serum biomarkers, viral burden, and histopathological changes leading to death.
Conclusions
Our observations in this model highlight the striking susceptibility of NHPs, and likely humans, via small-particle aerosol exposure to EBOV and emphasize the need for further development of diagnostics and postexposure prophylactics in the event of intentional release via deployment of an aerosol-producing device.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
Förderung
- NIEHS NIH HHS
- NIAID NIH HHS
- Defense Threat Reduction Agency
- Department of Health and Human Services, National Institutes of Health
Zitieren
APA
Prasad, A. N., Fenton, K. A., Agans, K. N., Borisevich, V., Woolsey, C., Comer, J. E., Dobias, N. S., Peel, J. E., Deer, D. J., Geisbert, J. B., Lawrence, W. S., Cross, R. W., & Geisbert, T. W. (2023). Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad137
Vancouver
Prasad AN, Fenton KA, Agans KN, Borisevich V, Woolsey C, Comer JE, et al. Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad137
BibTeX
@article{Prasad2023,
author = {Prasad, Abhishek N and Fenton, Karla A and Agans, Krystle N and Borisevich, Viktoriya and Woolsey, Courtney and Comer, Jason E and Dobias, Natalie S and Peel, Jennifer E and Deer, Daniel J and Geisbert, Joan B and Lawrence, William S and Cross, Robert W and Geisbert, Thomas W},
title = {Pathogenesis of Aerosolized Ebola Virus Variant Makona in Nonhuman Primates},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad137}
}
EUVIMED